Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
27 October 2008
American Academy of Neurology - Medical Specialty Society
Summary, Pubmed,
GUIDELINE OBJECTIVE(S)
To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies
TARGET POPULATION
Children and adults with refractory partial and generalized epilepsies
INTERVENTIONS AND PRACTICES CONSIDERED
Treatment
* Time to first seizure
* Percentage of patients rendered seizure free
* Time to exit of the study due to lack of efficacy or adverse events
* Incidence of adverse events
American Academy of Neurology - Medical Specialty Society
Summary, Pubmed,
GUIDELINE OBJECTIVE(S)To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies
TARGET POPULATION
Children and adults with refractory partial and generalized epilepsies
INTERVENTIONS AND PRACTICES CONSIDERED
Treatment
- Gabapentin (Neurontin)
- Lamotrigine (Lamictal)
- Topiramate (Topamax)
- Tiagabine (Gabitril)
- Oxcarbazepine (Trileptal)
- Levetiracetam (Keppra)
- Zonisamide (Zonegran)
* Time to first seizure
* Percentage of patients rendered seizure free
* Time to exit of the study due to lack of efficacy or adverse events
* Incidence of adverse events
